Literature DB >> 32023366

Evidence-Based Treatment of Premenstrual Dysphoric Disorder: A Concise Review.

Sara V Carlini1, Kristina M Deligiannidis2,1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32023366      PMCID： PMC7716347          DOI： 10.4088/JCP.19ac13071

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  24 in total

1.  A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.

Authors:  Ellen W Freeman; Steven J Sondheimer; Mary D Sammel; Tahmina Ferdousi; Hui Lin
Journal:  J Clin Psychiatry       Date:  2005-06       Impact factor: 4.384

2.  Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.

Authors:  Nirav R Shah; J B Jones; Jaclyn Aperi; Rachel Shemtov; Anita Karne; Jeff Borenstein
Journal:  Obstet Gynecol       Date:  2008-05       Impact factor: 7.661

3.  Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.

Authors:  Marie Bixo; Karin Ekberg; Inger Sundström Poromaa; Angelica Lindén Hirschberg; Aino Fianu Jonasson; Lotta Andréen; Erika Timby; Marianne Wulff; Agneta Ehrenborg; Torbjörn Bäckström
Journal:  Psychoneuroendocrinology       Date:  2017-03-01       Impact factor: 4.905

4.  Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.

Authors:  Peter J Schmidt; Pedro E Martinez; Lynnette K Nieman; Deloris E Koziol; Karla D Thompson; Linda Schenkel; Paul G Wakim; David R Rubinow
Journal:  Am J Psychiatry       Date:  2017-04-21       Impact factor: 18.112

5.  Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.

Authors:  E W Freeman; R Kroll; A Rapkin; T Pearlstein; C Brown; K Parsey; P Zhang; H Patel; M Foegh
Journal:  J Womens Health Gend Based Med       Date:  2001 Jul-Aug

6.  Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.

Authors:  Kimberly A Yonkers; Teri Pearlstein; Rana Fayyad; John A Gillespie
Journal:  J Affect Disord       Date:  2005-04       Impact factor: 4.839

7.  Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Cherri Miner; Eileen Brown; Susan McCray; Jill Gonzales; Madelaine Wohlreich
Journal:  Clin Ther       Date:  2002-03       Impact factor: 3.393

8.  Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.

Authors:  Joachim Marr; Klaas Heinemann; Michael Kunz; Andrea Rapkin
Journal:  Int J Gynaecol Obstet       Date:  2011-02-19       Impact factor: 3.561

9.  Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.

Authors:  Lee S Cohen; Cherri Miner; Eileen W Brown; Ellen Freeman; Uriel Halbreich; Karen Sundell; Susan McCray
Journal:  Obstet Gynecol       Date:  2002-09       Impact factor: 7.661

10.  Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.

Authors:  Elias Eriksson; Agneta Ekman; Suzanne Sinclair; Karin Sörvik; Christina Ysander; Ulla-Britt Mattson; Hans Nissbrandt
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153
View more
  1 in total

Review 1.  Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.

Authors:  Doodipala Samba Reddy
Journal:  J Neuroendocrinol       Date:  2021-09-10       Impact factor: 3.870
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.